Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025. “For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting,” said Dr. Musunuri. “I look forward to sharing more about Ocugen’s novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire disease and in turn large patient populations—in both rare and age-related blindness diseases.” Details regarding the fireside chat are as follows: Title: Fireside Chat with Aldeyra and Ocugen: Setting Sights on Inherited Retinal Dystrophies Date: Thursday, December 11, 2025 Location: Second Floor Ball